Home・Aandelen Lijst・Collegium Pharmaceutical Inc

C
Collegium Pharmaceutical Inc

Gesloten

SectorGezondheidszorg

35.58 0.71

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

34.65

Max

35.79

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.5M 14M
Verkoop	-12M 194M
K/W Sectorgemiddelde	17.077 64.641
EPS	1.76
Winstmarge	7.491
Werknemers	423
EBITDA	-213M 91M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+61.13% upside

Dividenden
By Acuity
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	31M 1.2B
Vorige openingsprijs	34.87
Vorige sluitingsprijs	35.58

Nieuwssentiment

By Acuity

34%

66%

104 / 340 Rangschikking in Healthcare

Collegium Pharmaceutical Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 19:46 UTC

Collegium Pharmaceutical Inc is trading lower today, continuing a three-session decline. The stock peaked early but has since pulled back.

31 jul 2026, 20:06 UTC

News

Collegium Pharmaceutical is under scrutiny due to concerns over its financial performance, contributing to a decline in shares during Friday's session.

30 jul 2026, 20:09 UTC

Collegium Pharmaceutical Inc shares are lower in Thursday's session, with no specific news to explain the decline amid broader market volatility.

29 jul 2026, 22:01 UTC

Collegium Pharmaceutical Inc is trading higher in after-market hours, continuing a positive trend with gains over four consecutive sessions amid cautious investor sentiment.

28 jul 2026, 22:01 UTC

Collegium Pharmaceutical Inc shares are lower in after-market hours, continuing a decline from Tuesday's close amid broader market pressures, particularly in Asia.

27 jul 2026, 19:07 UTC

News

Collegium Pharmaceutical reported first-quarter revenues of $193.5 million, surpassing expectations, while shares are trading higher amid broader strength in the pharmaceutical sector.

24 jul 2026, 19:46 UTC

Collegium Pharmaceutical Inc shares are lower during Friday's session, with no specific news identified to explain the decline. The stock remains near its one-month trading range.

22 jul 2026, 20:01 UTC

Collegium Pharmaceutical Inc shares are lower today, continuing a downward trend seen since Tuesday's close, with no specific news identified for the decline.

21 jul 2026, 20:01 UTC

Collegium Pharmaceutical Inc is trading higher amid a broader market rally, with the Pharmaceuticals sector also gaining momentum. No specific news was identified.

20 jul 2026, 19:41 UTC

News

Collegium Pharmaceutical plans to move its headquarters to Boston in 2027. Shares are lower amid significant declines in the Pharmaceuticals sub-sector.

Peer Vergelijking

Prijswijziging

Collegium Pharmaceutical Inc Prognose

Koersdoel

By TipRanks

61.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 57.33 USD 61.13%

Hoogste 60 USD

Laagste 56 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Collegium Pharmaceutical Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Collegium Pharmaceutical Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

104 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.